Doc description: Information Disclosure Statement (IDS) Filed Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

publisher, city and/or country where published.

PTO/SB/05e (04-09)
Approved for use through 05/01/2009 OMB 0651-0001
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number Filing Date		10528003
		2005-03-07
First Named Inventor	Danie	ele Franceschini
Art Unit		2617
Examiner Name	Herre	ra, D.
Attorney Docket Number		007511 00016

					U.S.	PATENTS			Remove	
Examiner Cite No Patent Number Kind Code1 Issue Date Name of Patentee or of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear							
	1									
If you wisl	h to a	ı dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	of cited Document		Releva	Columns,Lines where ant Passages or Release s Appear	e vant
	1									
If you wisl	h to a	ı dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add	
				FOREIG	GN PA1	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Document Country Kind Publication Ap		Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	Ts		
	1	02/35872	wo		A1	2002-05-02	Telecom Italia Lab	S.p.A.		
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	button	Add	-
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	_
Examiner Cite Initials* No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (block, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s).					Тs					

1	EP Office Action 2009 02-05, EP Applin, 03794984.9	

If you wish to add additional non-patent literature document citation information please click the Add button Add

FXAMINER SIGNATURE

Examiner Signature Date Considered Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Petent Documents at Invest_USETO_GOL/or MPEP 901.04. 2 Enter office that issued the document, by the Involved row (MPD Standard ST.3). 3 "For Lapraence patient for counters, the orbidation of the year of the register or many precess the serial runber of the patient document.

Virid of Socurent by the appropriate symbols as endicated on the document under WIPO Standard ST.16 if possible. **Applicant is to place a check mark here if English languages translation is altitacted.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10528003		
	Filing Date		2005-03-07		
First Named Inventor Danie		Danie	le Franceschini		
	Art Unit		2617		
	Examiner Name	Непте	ra, D.		
	Attorney Docket Numb	er	007511.00016		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the	appropriate selection(s):
---------------	----------	-------------	----------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _ ...

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Gary D. Fedorochko/	Date (YYYY-MM-DD)	2009-05-22
Name/Print	Gary D. Fedorochko	Registration Number	35509

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR
1.14. This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Tradenski offices, V.S. pepariment of Commence, P. 0. Dex 1450, Alexandri, V.S. 2213-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, VA.2213-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.